AI PRICE FORECAST
ZTS Stock Forecast & AI Price Prediction
Zoetis · Healthcare · Drug Manufacturers - Specialty & Generic
ZTS live signal snapshot
Shares of ZTS were last at $82.57, up 0.13% on the day, trading 37.7% below its 52-week high of $132.49 and 20.1% above its 52-week low of $68.77. The model's verdict for ZTS right now: BUY (70% confidence). The short-term averages are tangled, giving no clean trend signal either way. Its one-month projection is about $86.32, a 4.5% move from the last price.
ZTS's 14-day RSI is 52.8 — a neutral zone, with no decisive edge for bulls or bears. The MACD indicator trails its signal line, with a histogram of -0.08 pointing to selling pressure. Its 50-day average ($76.00) remains 17.3% below the 200-day ($91.87), the pattern chartists call a death cross.
13 Wall Street analysts covering ZTS put the average price target at $89.69 (range $73.00–$115.00), implying 8.6% upside from the current price. The current recommendation trend leans bullish: 6 Buy/Strong Buy ratings vs 0 Sell/Strong Sell (and 10 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive ZTS dashboard for numbers updated throughout today's session.
About Zoetis
Zoetis Inc. (ZTS) is a drug manufacturers - specialty & generic company in the healthcare sector, headquartered in Parsippany, NJ, United States. Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry… It has a market value of about $33.5 billion and roughly 14,500 full-time employees. With a beta of 0.68, the stock has historically moved less than the overall market.
ZTS performance vs. the market
ZTS is down 34.4% so far in 2026, behind the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has lost 31.1%, 42.6 points worse than the S&P 500. Its +11.1% move over the past month extends a +8.9% three-month run.
| Period | ZTS | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +11.1% | +11.4% | −2.3% |
| 3 months | +8.9% | +12.2% | −2.3% |
| Year to date | −34.4% | +22.1% | +11.4% |
| 1 year | −31.1% | +28.3% | +11.5% |
Zoetis financials at a glance
Zoetis's most recent quarter (ended Sep 30, 2026) brought in $2.4 billion of revenue and net income of $591 million (a 24.7% net margin). Revenue was down 1.3% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 14.0 on trailing earnings of $5.88 per share. Trailing free cash flow was $2.1 billion, and total debt equals 280% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $2.4B | $591M |
| Jun 30, 2026 | $2.5B | $691M |
| Mar 31, 2026 | $2.3B | $601M |
| Dec 31, 2025 | $2.4B | $603M |
ZTS vs. its peers
ZTS's −34.4% this year ranks ahead of 0 of the 5 big healthcare names below. The strongest of the group this year is Merck & Co. (MRK, +39.8%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Zoetis (ZTS) | $82.57 | −34.4% | 14.0 | BUY |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
| Johnson & Johnson (JNJ) | $280.41 | +35.5% | 42.6 | BUY |
| AbbVie (ABBV) | $294.98 | +29.1% | 50.7 | BUY |
| Merck & Co. (MRK) | $147.18 | +39.8% | 148.7 | HOLD |
| UnitedHealth Group (UNH) | $402.94 | +22.1% | 23.0 | HOLD |
ZTS stock: common questions
What is the ZTS stock price target?
13 Wall Street analysts put the average 12-month target at $89.69, in a range of $73.00–$115.00, versus a recent price of $82.57. Stock Pulse 247's model projects about $86.32 over the next month.
Is ZTS a buy right now?
Our AI model currently rates ZTS a BUY at 70% confidence. Among analysts, 6 rate it Buy or Strong Buy, 10 Hold and 0 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has ZTS stock performed this year?
ZTS is down 34.4% so far in 2026, behind the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has lost 31.1%, 42.6 points worse than the S&P 500. Its +11.1% move over the past month extends a +8.9% three-month run.
What is ZTS's 52-week high and low?
ZTS has traded between $68.77 and $132.49 over the past 52 weeks; at $82.57 it is 37.7% below its 52-week high of $132.49 and 20.1% above its 52-week low of $68.77.
What sector is ZTS in, and who are its peers?
ZTS is in the healthcare sector (drug manufacturers - specialty & generic). Its largest peers on Stock Pulse 247 include Eli Lilly and (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co. (MRK).
How accurate is the ZTS forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines ZTS's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.